ClinicalTrials.gg
Not yet recruitingNCT07544498XR2ESILIENCEUpdated May 18, 2026

XR2ESILIENCE - XR-Based Resilience Training for Stress and Mental Health in Healthcare Workers

An interventional study of XR-based Resilience Training and Waitlist Control in Occupational Stress, Work-Related Stress and Mental Health, sponsored by Medical University of Graz. Not yet recruiting at 8 sites in 5 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Medical University of Graz · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Occupational Stress with a site in Spain — 3 open to participants now, 3 under way, none of them phase 3. Occupational Stress · Spain.

Started
2026
with 2 others
No phase
8 of 10
3 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Medical University of Graz

Among the 10 studies in Occupational Stress with a site in Spain, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 8th registered.

Occupational Stress

238 studies on the registry are indexed under Occupational Stress; 64 are open to participants now.

Browse Occupational Stress studies →

Open to participants now

3 of the 10 studies in Occupational Stress with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 33 Occupational Stress studies recruiting now, 17 (52%) set no upper age limit and 13 (39%) stop at 75 or younger; 4 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Occupational Stress with a site in Spain, or all of them as a file.
02

Study summary

This study investigates the effectiveness of an extended reality (XR) based resilience training program designed to support the mental health and well-being of nurses working in hospital settings. Nurses are exposed to high emotional, cognitive, and organizational demands and show elevated levels of work-related stress and stress-associated mental health problems. Strengthening resilience and coping capacities is therefore an important preventive approach to support nurses' well-being and sustain quality of care.

The study is conducted as a pragmatic randomized controlled trial with a waitlist control group and includes approximately 232 nurses from hospitals in several European countries. Participants are randomly assigned either to an XR-based resilience training group or to a waitlist control group that continues with care as usual during the waiting period. The XR-based intervention consists of eight immersive training sessions delivered over approximately ten weeks using a head-mounted display. The training focuses on behavioral, cognitive, and emotional coping strategies and aims to enhance key resilience factors such as problem-solving, cognitive reappraisal, emotion regulation, and positive self-care.

The primary outcome is perceived stress, assessed using the Perceived Stress Scale. Secondary outcomes include resilience, occupational self-efficacy, quality of life, psychological distress, burnout symptoms, coping strategies, work-related rumination, and turnover intentions. Assessments are conducted at baseline, post-intervention, and at a 20-week follow-up. In addition, a subgroup of participants will optionally provide physiological data during selected XR sessions to explore digital biomarkers related to stress and recovery.

The findings of this study will provide evidence on the effectiveness, feasibility, and acceptance of XR-based resilience training for nurses and inform future implementation of digital mental health interventions in healthcare workplaces.

Read the detailed description

This study is part of the XR2ESILIENCE project, a European multicenter research initiative aimed at promoting resilience and mental health among healthcare professionals through innovative extended reality (XR) technologies. The present randomized controlled trial evaluates the effectiveness of a newly developed XR-based resilience training program for nurses working in hospital settings.

Nurses are frequently exposed to high workload, emotional labor, time pressure, and organizational stressors, which are associated with increased stress levels, burnout symptoms, and mental health impairments. Despite the high relevance of resilience promotion in this occupational group, accessible and scalable preventive interventions remain limited. XR technology offers the opportunity to deliver immersive, engaging, and standardized resilience training that can be flexibly integrated into clinical and non-clinical settings.

The study uses a pragmatic, parallel-group, waitlist-controlled randomized design. A total of approximately 232 nurses aged 18 to 65 years will be recruited across multiple hospital sites in Europe. After completion of baseline assessments and provision of informed consent, participants are randomly allocated in a 1:1 ratio either to the XR-based intervention group or to a waitlist control group. The control group continues with care as usual and receives access to the intervention after the waiting period.

The XR-based resilience training consists of eight sessions delivered over approximately ten weeks using a standalone head-mounted display. Each session lasts around 20 to 30 minutes. The training is structured into modules addressing behavioral coping (e.g., problem-solving and proactive coping), cognitive coping (e.g., appraisal and reappraisal of stressors), and emotional coping (e.g., emotion regulation, acceptance, and fostering positive emotions). The intervention is theoretically grounded in contemporary resilience frameworks and the concept of regulatory flexibility. Participants complete the sessions individually, with technical support available if needed.

The primary outcome is perceived stress measured by the 10-item Perceived Stress Scale at post-intervention. Secondary outcomes include resilience, occupational self-efficacy, psychological distress, burnout symptoms, coping strategies, work-related rumination, quality of life, and career-related variables such as turnover intentions. Data are collected at baseline, immediately after the intervention period, and at a 20-week follow-up.

In addition to questionnaire-based outcomes, optional digital biomarker data are collected during selected XR sessions to explore physiological indicators of stress and recovery, such as heart rate variability and other sensor-based measures, depending on study site capabilities. User experience, technology acceptance, satisfaction, and potential side effects of XR use are assessed descriptively after completion of the intervention.

The study follows an intention-to-treat approach for primary analyses. Results are expected to provide robust evidence on whether XR-based resilience training can reduce perceived stress and improve mental health outcomes among nurses. The findings will also inform the feasibility, acceptability, and potential health-economic value of implementing XR-supported resilience interventions in hospital workplaces.

03

Conditions studied

  • Occupational Stress
  • Work-Related Stress
  • Mental Health
  • Burnout
  • Resilience

Keywords

  • Extended Reality
  • Virtual Reality
  • XR-based Intervention
  • Resilience Training
  • Stress Reduction
  • Nurses
  • Healthcare Workers
  • Occupational Health
  • Mental Well-Being
  • Digital Mental Health
  • Preventive Intervention
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. working as a nurse in direct patient care within a clinical setting;
  2. working at least 10h/week in their profession;
  3. speaking the language in which the RCT is conducted sufficiently well;
  4. able and willing to participate in all aspects of the study;
  5. understanding and signing the appropriate form.

Exclusion criteria

Exclusion Criteria:

  1. a diagnosed severe mental disorder associated with alterations in reality perception (e.g., delusions, hallucinations, derealization, depersonalization, or dementia), including in particular schizophrenia, bipolar disorder, severe major depressive disorder, or other psychotic disorders (lifetime);
  2. a current major depressive episode or a current post-traumatic stress disorder (PTSD);
  3. an acute or medical condition that may interfere with the safe use of an XR headset or study participation, including but not limited to epilepsy, pronounced dizziness, balance disorders, or acute cardiovascular conditions;
  4. an acute eye infection (e.g., conjunctivitis);
  5. unstable medication related to a mental health condition, defined as recent changes in dosage or class of psychotropic medication;
  6. initiation of psychotherapy or any structured stress-management training within the past three months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    XR-based Resilience Training

    Participants in this arm receive an XR-based resilience training consisting of eight immersive sessions delivered over approximately ten weeks using a head-mounted display. The training focuses on behavioral, cognitive, and emotional coping strategies and aims to strengthen resilience and stress management skills. Each session lasts approximately 20 to 30 minutes and is completed individually.

    Behavioral: XR-based Resilience Training · Other: Waitlist Control

  • No intervention
    Waitlist Control

    Participants in this arm are assigned to a waitlist control condition and continue with care as usual during the waiting period. They do not receive the XR-based resilience training during the first ten weeks of the study but are offered access to the intervention after completion of the post-intervention assessment.

Interventions

  • BehavioralXR-based Resilience Training

    The XR-based resilience training is delivered via a standalone extended reality head-mounted display and consists of eight immersive sessions over approximately ten weeks. The training addresses behavioral coping strategies such as problem solving, cognitive coping strategies such as appraisal and reappraisal of stressors, and emotional coping strategies including emotion regulation and positive self-care. Sessions last approximately 20 to 30 minutes and are completed individually with technical support available if needed.

  • OtherWaitlist Control

    Participants assigned to the waitlist control condition receive no active intervention during the initial study period and continue with care as usual. After completion of the post-intervention assessment, participants are offered access to the XR-based resilience training.

06

What researchers measure

Primary outcomes

  1. Perceived Stress Assessed by PSS-10

    Perceived stress measured using the 10-item Perceived Stress Scale (PSS-10). The PSS-10 assesses the degree to which situations in one's life are appraised as stressful during the past month. Scores range from 0 to 40, with higher scores indicating higher perceived stress.

    Time frame: Baseline, 10 weeks post-randomization & 20 weeks post-randomization

Secondary outcomes

  1. Resilience Assessed by BRS

    Self-perceived resilience will be assessed using the Brief Resilience Scale (BRS), a self-report measure consisting of six items rated on a 5-point Likert scale. Total scores are calculated by summing item responses (range: 6 to 30) and dividing by the number of items answered, resulting in a mean score ranging from 1 to 5. Higher scores indicate greater resilience.

    Time frame: Baseline, 10 weeks post-randomization & 20 weeks post-randomization

  2. Occupational Self-Efficacy Assessed by OSE-SF

    Occupational self-efficacy will be assessed using the Occupational Self-Efficacy Scale - Short Form (OSE-SF), a self-report measure consisting of items rated on a 6-point Likert scale ranging from 1 (not at all true) to 6 (completely true). Total scores are calculated by summing item responses, with higher scores indicating greater occupational self-efficacy.

    Time frame: Baseline and 10 weeks post-randomization

  3. Psychological Distress Assessed by GHQ-12

    Psychological distress will be assessed using the General Health Questionnaire-12 (GHQ-12), a 12-item self-report measure with items rated on a 4-point Likert scale (0 to 3). Total scores range from 0 to 36, with higher scores indicating greater psychological distress.

    Time frame: Baseline and 10 weeks post-randomization

  4. Burnout symptoms Assessed by BAT-12

    Burnout symptoms will be assessed using the Burnout Assessment Tool - Short Version (BAT-12), a 12-item self-report measure with items rated on a 5-point Likert scale ranging from 1 (never) to 5 (always). Total scores range from 12 to 60, with higher scores indicating higher levels of burnout-related symptoms.

    Time frame: Baseline and 10 weeks post-randomization

  5. Coping Strategies Assessed by CSI-SF

    Coping strategies will be assessed using the Coping Strategies Inventory - Short Form (CSI-SF). The CSI-SF is a 16-item measure rated on a 5-point Likert scale ranging from 1 to 5. Subscale scores range from 4 to 20, with higher scores indicating greater use of coping strategies.

    Time frame: Baseline, 10 weeks post-randomization & 20 weeks post-randomization

  6. Coping Flexibility Assessed by CFS-R

    Coping flexibility will be assessed using the Coping Flexibility Scale - Revised (CFS-R). The CFS-R is a 10-item measure rated on a 4-point Likert scale ranging from 0 to 3. Total scores range from 0 to 30, with higher scores indicating greater coping flexibility.

    Time frame: Baseline, 10 weeks post-randomization & 20 weeks post-randomization

  7. Health-Related Quality of Life Assessed by EQ-5D-5L

    Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L), a standardized instrument comprising five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-level scale (1 to 5). Health states are converted into a single index value using a country-specific value set, typically ranging from less than 0 (worse than death) to 1 (full health), with higher values indicating better perceived health status.

    Time frame: Baseline and 10 weeks post-randomization

  8. Turnover intentions

    Turnover intentions assessed using self-developed items measuring intention to leave the profession or current workplace.

    Time frame: Baseline and 10 weeks post-randomization

  9. User Experience Assessed With the AttrakDiff Mini

    User experience will be assessed using the AttrakDiff Mini. The AttrakDiff Mini is a 10-item measure rated on a 7-point bipolar scale ranging from -3 to +3. Higher scores indicate a more positive user experience.

    Time frame: 10 weeks post-randomization (Training Group) or 20 weeks post-randomization (Control Group)

  10. User Satisfaction Assessed With the Client Satisfaction Questionnaire for Internet-Based Interventions

    User satisfaction will be assessed using the Client Satisfaction Questionnaire adapted for Internet-based interventions (CSQ-I). The CSQ-I is an 8-item measure rated on a 4-point Likert scale. Total scores range from 8 to 32, with higher scores indicating greater satisfaction.

    Time frame: 10 weeks post-randomization (Training Group) or 20 weeks post-randomization (Control Group)

  11. VR-Related Side Effects Assessed With the Virtual Reality Neuroscience Questionnaire

    VR-related side effects will be assessed using the Virtual Reality Neuroscience Questionnaire (VRNQ), specifically the Virtual Reality-Induced Symptoms and Effects (VRISE) subscale. Items are rated on a 7-point Likert scale, with higher scores indicating lower intensity of side effects.

    Time frame: 10 weeks post-randomization (Training Group) or 20 weeks post-randomization (Control Group)

  12. Positive Effects Assessed With Adapted Items From the Oxford VR Side Effects Checklist

    Positive effects will be assessed using three adapted items from the Oxford VR Side Effects Checklist (O-VRES). Items are rated on a 5-point Likert scale. Total scores range from 3 to 15, with higher scores indicating greater endorsement of positive effects.

    Time frame: 10 weeks post-randomization (Training Group) or 20 weeks post-randomization (Control Group)

07

Study locations

8 sites
  • Medical University of Graz, Clinical Division of Psychiatry and Psychotherapeutic Medicine
    Graz, Styria 8036, Austria
    • Melissa L Behrend, MSc · Contactmelissa.behrend@medunigraz.at · +43 316 385 30081
    • Nina Dalkner, Res.-Prof. Priv.-Doz. Mag. Dr. · Principal investigator
  • Klinika za psihijatriju Sveti Ivan
    Zagreb, 10000, Croatia
    • Ena Ivezic, mag. psih. · Contactena.ivezic@pbsvi.hr · +385 1 3430 171
    • Igor Filipcic, Prof. prim. dr. sc. · Principal investigator
  • University Medical Center of Johannes Gutenberg University Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
    • Annika Hasch, MSc · ContactAnnika.Hasch@lir-mainz.de · +49 6131 89448 00
    • Klaus Lieb, Prof. Dr. · Principal investigator
  • Hospital José Joaquim Fernandes
    Beja, Beja District 7801-849, Portugal
    • Fátima Cano · Contactfatima.cano@uevora.pt
    • Elisabete Alves · Sub investigator
    • Lara Guedes de Pinho, Prof. PhD Dr. · Principal investigator
  • Del Henares University Hospital
    Coslada, Madrid 28822, Spain
  • Summa 112
    Madrid, Madrid 28005, Spain
  • Infanta Leonor University Hospital
    Madrid, Madrid 28031, Spain
  • Infanta Sofía University Hospital
    San Sebastián de los Reyes, Madrid 28702, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request. Data will be shared in a pseudonymized form to qualified researchers for purposes of academic research and secondary analyses that are consistent with the original study objectives. Requests will be reviewed by the study steering committee and require a methodologically sound proposal and a data use agreement. Data sharing will be subject to applicable data protection regulations and ethical approvals.

Time frame: Beginning 6 months after publication of the primary results and ending 5 years thereafter

Access criteria: Researchers must submit a written request including a study proposal statistical analysis plan and intended use of the data. Approval by the study steering committee and a signed data use agreement are required prior to data access.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.

Of 128 non-industry interventional studies with no phase under Occupational Stress, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 18 months is above that.

Counting every sponsor, half of 136 studies reached it within 10 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 22, 2026
StartEst.
Sep 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07544498
Collaborators
MINDCONSOLE GMBH, Medizinische Privatuniversität Burgenland, Central Institute of Mental Health, Mannheim, St. Pölten University of Applied Sciences, University of Évora, Leibniz Institute for Resilience Research (LIR), Mainz, Germany, Leuphana Universität Lünenberg, University of Lisbon, Sveti Ivan Psychiatric Hospital, mindconsole, PredictBy Research and Consulting, S.L, Servicio Madrileño de Salud (SERMAS)
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Sep 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
May 18, 2026

Study contacts

Nina Dalkner Research Prof. Priv.-Doz. Mag. rer.nat. Dr. rer.nat.
Contact
nina.dalkner@medunigraz.at
+43 316 385 30081

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion